Clinical trial Recruiting at 1 site Observational Ages 0 to 21

Investigating Dead Space and Inhaled Nitric Oxide in Children with Acute Respiratory Distress Syndrome

Official title: Dead Space and Inhaled Nitric Oxide in Pediatric Acute Respiratory Distress Syndrome

Run by Children's Hospital Los Angeles · NCT06690801 · Data updated 2026-11-12

This study is testing if a specific marker can help predict the risk of death in children with acute respiratory distress syndrome and see how well inhaled nitric oxide treatment works for them.

More Acute Respiratory Distress Syndrome trials

Quick facts

Study typeObservational
Ages0 Years to 21 Years
SexAll
Enrollment1260 (estimated)
SponsorChildren's Hospital Los Angeles
Academic / other
Locations10 sites (Los Angeles, California and 9 other locations)
StatusRecruiting
StartedOctober 3, 2024
Main results expectedDecember 1, 2028
Study endsFebruary 1, 2029
Registry record updatedNovember 15, 2024
Trial IDNCT06690801 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include children aged over 37 weeks corrected gestational age to 21 years who are mechanically ventilated and meet the criteria for moderate to severe pediatric ARDS.

Probably not a fit

Patients receiving non-conventional invasive mechanical ventilation or those not meeting the ARDS criteria may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the association between a specific marker of dead space (AVDSf) and mortality risk in pediatric patients with acute respiratory distress syndrome (ARDS). It will also explore whether AVDSf can indicate variability in the treatment effects of inhaled nitric oxide (iNO) therapy. The study will involve 1260 mechanically ventilated children, with a subgroup of 450 children providing longitudinal blood samples to assess microvascular dysfunction. The goal is to enhance risk stratification and treatment personalization for children suffering from ARDS.

Why it matters

Potential benefit: If successful, this study could improve risk assessment and treatment strategies for children with acute respiratory distress syndrome.

How similar studies have gone: While the approach of using AVDSf as a marker in ARDS is innovative, similar studies have shown promise in understanding treatment effects in respiratory conditions.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age \>37 weeks corrected gestational age to 21 years, including adults lacking the capacity to consent.
* Within 72 hours of the start of invasive mechanical ventilation and meet the criteria for pediatric ARDS (new infiltrate on chest imaging and a known ARDS risk factor within 7 days of the onset of hypoxemia) and either meet criteria for moderate or severe pediatric ARDS between 4-72 hours of IMV (OI ≥ 8 or OSI ≥ 7.5) OR have an OI ≥ 20 or an OSI ≥ 14 x 15 minutes between 0-4 hours of IMV.
* Subgroup of children eligible for longituduinal Blood Collection: Children with severe PARDS (OI ≥ 16 or an OSI ≥ 12 between 4-72 hours of IMV) or those with an OI ≥ 20 or an OSI ≥ 14 for 15 minutes between 0-4 hours of IMV will be eligible for collection of longitudinal plasma samples.

Exclusion Criteria:

* Non-conventional invasive mechanical ventilation (i.e. High Frequency Oscillatory Ventilation, Airway Pressure Release Ventilation) at the time of ICU admission
* ECMO or iNO (or other inhaled pulmonary vasodilator therapy) at the time of ICU admission
* Significant lower airways obstruction (examination of ventilator and capnography waveforms by site study or medical team)
* Air leak \>20% (endotracheal tube, tracheostomy tube, or thoracostomy tube)
* Home Invasive Mechanical Ventilation
* Cyanotic Congenital Heart Disease
* Previous enrollment in the DiNO study
* Do not resuscitate order at the time of pediatric ARDS diagnosis.
* Blood gas not obtained prior to initiation of ECMO, iNO, or non-conventional ventilation.

Where it's running

  • Children's Hospital Los Angeles
    Los Angeles, California, United States
    Recruiting
  • Children's Hospital Colorado
    Denver, Colorado, United States
    Not yet recruiting
  • Boston Children's Hospital
    Boston, Massachusetts, United States
    Not yet recruiting
  • University of Michigan / CS Mott Children's Hospital
    Ann Arbor, Michigan, United States
    Active not recruiting
  • University of Nebraska Medical Center / Children's Hospital and Medical Center
    Omaha, Nebraska, United States
    Not yet recruiting
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio, United States
    Not yet recruiting
Show 4 more locations
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania, United States
    Not yet recruiting
  • Texas Children's Hospital Baylor College of Medicine
    Houston, Texas, United States
    Not yet recruiting
  • American Family Children's Hospital / University of Wisconsin-Madison
    Madison, Wisconsin, United States
    Not yet recruiting
  • Children's Hospital of Wisconsin / Medical College of Wisconsin
    Milwaukee, Wisconsin, United States
    Not yet recruiting

Study contacts

  • Principal investigator: Anoopindar M Bhalla, MD — Children's Hospital Los Angeles
  • Study coordinator: Jeni Kwok
  • Email: dinostudy@chla.usc.edu
  • Phone: 3233617939

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.